CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk [Updated]

The CHA2DS2-VASc score is a widely used tool for assessing the annual risk of thromboembolic events and stroke in patients with atrial fibrillation (AF). The score has been validated in numerous studies across various patient populations and settings. The score assigns points to risk factors, including congestive heart failure, hypertension, age, diabetes, previous stroke or transient ischemic attack, vascular disease, age over 75, sex, and presence of vascular disease. Recent guidelines emphasize the benefit of anticoagulation over antiplatelet therapy, recommending that patients with non-valvular AF and a CHA2DS2-VASc score of 0 (men) or 1 (women) typically do not require anticoagulation. However, anticoagulation should be considered for scores of 1 in men and 2 in women and is recommended for scores greater than 2 in men and 3 in women. The role of sex in the score has been reconsidered, with new evidence suggesting its removal could lead to a more unified approach to anticoagulation, as exemplified by the updated CHA2DS2-VA score adopted in the 2024 European Society of Cardiology guidelines. This ongoing research highlights the evolving nature of risk stratification tools in AF management, with potential modifications to the CHA2DS2-VASc score to better reflect current understanding and clinical practice.